Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Combining endocrine therapy with targeted agents in luminal breast cancer

Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the challenges of treating luminal type breast cancer, which generally has a better prognosis with conventional treatment, and the need to carefully select patients to avoid additional toxicity. Combining endocrine therapy with targeting agents, such as CDK4/6 inhibitors and MTOR inhibitors, has the potential to improve patient outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

It’s a very difficult situation at this moment because many of the luminal type breast cancer can have a better prognosis in general by conventional treatment. So for avoiding the additional toxicity, so we need to think about how to titrate the patient population. And also there are other drugs such as CDK4/6 inhibitors coming next generation or third. So this kind of thing, this kind of drug can get a more preferable prognosis for such kind of patients...

It’s a very difficult situation at this moment because many of the luminal type breast cancer can have a better prognosis in general by conventional treatment. So for avoiding the additional toxicity, so we need to think about how to titrate the patient population. And also there are other drugs such as CDK4/6 inhibitors coming next generation or third. So this kind of thing, this kind of drug can get a more preferable prognosis for such kind of patients. So the combination of endocrinotherapy, targeting agent, MTOR inhibitor, probably patients may have more benefit than before.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.